Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAND567 + Carboplatin in Recurrent Ovarian Cancer
NCT06087289Phase 2Completed
- Sponsor
- Kancera
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of rugocrixan in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Kancera. Started Apr 2023; status: completed.
02
Drugs
rugocrixan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06087289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087289.